Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.35 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.35 |
| ▸ | FDPS | P14324 | 2/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL8741366 | 0.81 | ALDH1A1 (0.60) | LPAR3LPAR2ALDH1A1LMNABLM | |
| Phosphoric Acid SCHEMBL270146 | 0.81 | — | — | |
| Phosphoric Acid SCHEMBL278406 | 0.81 | ALDH1A1 (0.60) | LPAR3LPAR2ALDH1A1LMNABLM | |
| SCHEMBL132037 | 0.80 | — | — | |
| Phosphoric Acid SCHEMBL740513 | 0.79 | ALDH1A1 (0.56) | LPAR3LPAR2ALDH1A1LMNABLM | |
| Phosphoric Acid SCHEMBL29098368 | 0.79 | ALDH1A1 (0.56) | LPAR3LPAR2ALDH1A1LMNABLM | |
| Phosphoric Acid SCHEMBL3254037 | 0.79 | ALDH1A1 (0.56) | LPAR3LPAR2ALDH1A1LMNABLM | |
| Urea SCHEMBL1179739 | 0.79 | — | — | |
| Iodide SCHEMBL19205926 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL10786924 | 0.77 | ALDH1A1 (0.50) | ALDH1A1LMNABLMTSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4578503-A2 | NON-VIRAL IMMUNO-TARGETING | University of Washington (US) | 2025-07-02 | — | — | EP | claimed |
| US-20240131184-A1 | COMPOSITIONS AND METHODS FOR DELIVERING NUCLEIC ACIDS TO CELLS | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-04-25 | — | — | US | claimed |
| US-20220280652-A1 | NON-VIRAL IMMUNO-TARGETING | UNIVERSITY OF WASHINGTON (US) | 2022-09-08 | — | — | US | claimed |
| EP-3997109-A2 | NON-VIRAL IMMUNO-TARGETING | University of Washington (US) | 2022-05-18 | — | — | EP | claimed |
| CN-114174322-A | Non-viral immune targeting | 华盛顿大学 | 2022-03-11 | — | — | CN | claimed |
| WO-2026098737-A1 | NUCLEIC ACID CONJUGATE AND PHARMACEUTICAL COMPOSITION FOR LIPID DELIVERY, AND USE THEREOF | 苏州时安生物技术有限公司 | 2026-05-15 | — | — | WO | disclosed |
| WO-2026098677-A1 | DOUBLE-STRANDED RNA FOR REGULATING ALK7 EXPRESSION, CONJUGATE THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 苏州时安生物技术有限公司 | 2026-05-15 | — | — | WO | disclosed |
| WO-2026098453-A1 | DOUBLE-STRANDED RIBONUCLEIC ACID FOR INHIBITING GPR146 GENE EXPRESSION, CONJUGATE, AND USE | 北京福元医药股份有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-12624355-B2 | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof | Suzhou Ribo Life Science Co., Ltd. (CN) | 2026-05-12 | — | — | US | disclosed |
| US-20260125684-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2026-05-07 | — | — | US | disclosed |
| US-20260092280-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2026-04-02 | — | — | US | disclosed |
| US-12590304-B2 | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | Suzhou Ribo Life Science Co., Ltd. (CN) | 2026-03-31 | — | — | US | disclosed |
| WO-2020038377-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, AND USE THEREOF | 苏州瑞博生物技术有限公司 | 2020-02-27 | — | — | WO | disclosed |
| CN-108431224-B | Small interfering nucleic acid, pharmaceutical composition and application thereof | 苏州瑞博生物技术有限公司 | 2020-01-17 | — | — | CN | disclosed |
| CN-108431224-A | A kind of small RNA and medical composition and its use | 苏州瑞博生物技术有限公司 | 2018-08-21 | — | — | CN | disclosed |
| CN-108265052-A | A kind of small RNA and medical composition and its use | 苏州瑞博生物技术有限公司 | 2018-07-10 | — | — | CN | disclosed |
| CN-108239644-A | A kind of small RNA and medical composition and its use | 苏州瑞博生物技术有限公司 | 2018-07-03 | — | — | CN | disclosed |
| CN-108210510-A | A kind of small RNA medical composition and its use | 苏州瑞博生物技术有限公司 | 2018-06-29 | — | — | CN | disclosed |
| CN-108220293-A | Small interfering nucleic acid, pharmaceutical composition and application thereof | 苏州瑞博生物技术有限公司 | 2018-06-29 | — | — | CN | disclosed |
| CN-107849567-A | A kind of siRNA, the pharmaceutical composition containing the siRNA and conjugate and their application | 苏州瑞博生物技术有限公司 | 2018-03-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092280-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | F13B, F13A1, F11 | ADRB3 4261/4885LPAR3 1581/4885LPAR2 2022/4885 |
| US-20240131184-A1 | COMPOSITIONS AND METHODS FOR DELIVERING NUCLEIC ACIDS TO CELLS | NUP205, HNRNPH3, NSUN2 | ADRB3 4145/4885LPAR3 451/4885LPAR2 802/4885 |
| US-12590304-B2 | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | RNGTT, SSU72, SUB1 | ADRB3 1180/4885LPAR3 1505/4885LPAR2 1539/4885 |
| US-12624355-B2 | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof | RNGTT, RNMT, NSUN2 | ADRB3 2335/4885LPAR3 851/4885LPAR2 836/4885 |
| US-20260125684-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | PCSK9, PCSK7, NSUN2 | ADRB3 3010/4885LPAR3 396/4885LPAR2 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.